Jemperli (Dostarlimab)

Dostarlimab is a monoclonal antibody that blocks the PD‑1 receptor on T cells, preventing its interaction with PD‑L1 and PD‑L2 on tumour cells. This blockade restores T‑cell activity, allowing the immune system to recognise and destroy cancer cells that would otherwise evade immune detection.

The dosing regimen for Jemperli is determined by the prescribing oncologist based on the patient’s clinical condition, body weight, and treatment protocol. Healthcare professionals set the dose and schedule according to approved guidelines and individual patient factors.

Safety of Jemperli in pregnancy or while breastfeeding has not been established. Women of child‑bearing potential should be advised of potential risks and use effective contraception. Breastfeeding decisions should be made after discussing possible effects with a healthcare provider.

To order Jemperli, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Jemperli (dostarlimab) belongs to the same class as pembrolizumab and nivolumab, sharing the PD‑1 target. Clinical data suggest comparable efficacy in dMMR tumours, with a safety profile consistent with the class. Choice among agents often depends on regulatory approval, dosing schedule, and individual patient considerations.

Jemperli must be stored refrigerated at 2‑8 °C. Keep the vials in the original packaging, protect them from light, and avoid freezing or shaking. If temporary storage at room temperature is unavoidable, limit exposure to no more than 30 minutes before administration.

Jemperli is supplied as a sterile solution for intravenous infusion. It is administered by a qualified healthcare professional, typically over a period of 30 minutes to one hour, following the dosing schedule prescribed by the treating oncologist.

Serious risks include immune‑mediated adverse events such as colitis, pneumonitis, hepatitis, severe skin reactions, endocrinopathies, and myocarditis. Patients should be monitored closely for symptoms like persistent diarrhea, shortness of breath, jaundice, rash, or unexplained fatigue and report them promptly.

Jemperli is contraindicated in patients with known hypersensitivity to dostarlimab or any of its excipients. It should also be avoided in individuals receiving other immune checkpoint inhibitors concurrently, and caution is advised for patients with active autoimmune diseases or uncontrolled infections.